Epizyme Announces Date of First Quarter 2021 Financial Results
Epizyme (Nasdaq: EPZM) is set to host a conference call and webcast on May 6, 2021, at 7:30 a.m. ET to discuss its first quarter 2021 financial results and business updates. The company, focused on novel epigenetic therapies, has one FDA-approved product, TAZVERIK® (tazemetostat), indicated for certain types of cancer. Continued approval for TAZVERIK is contingent upon clinical benefit verification in further trials. Join the call by dialing (877) 844-6886 for domestic or (970) 315-0315 for international access.
- Epizyme has one FDA-approved product, TAZVERIK, for several cancer indications.
- The company is actively researching further applications of TAZVERIK in various malignancies.
- Continued approval of TAZVERIK is contingent upon successful verification of clinical benefits in confirmatory trials.
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2021 financial results and provide a business update on Thursday, May 6, 2021 at 7:30 a.m. ET.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 4139845. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call.
About Epizyme, Inc.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.
TAZVERIK® is a registered trademark of Epizyme, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005135/en/
FAQ
When is Epizyme's first quarter 2021 financial results call?
What product has Epizyme received FDA approval for?
What are the indications for TAZVERIK?
How can I join Epizyme's conference call?
What is the future outlook for TAZVERIK?
